Drug intelligence / Profile preview

CTA-01

Development stage: Preclinical
Lead developer: CTCELLS
Modality: Antibody-Based Therapeutics

Overview

CTA-01 is an antibody drug developed by CTCELLS, Inc. It functions as an antagonist of the Epidermal Growth Factor Receptor (EGFR) and is currently in preclinical development. Its therapeutic potential is being explored for various neoplasms, digestive system disorders, and respiratory diseases, with active indications including colorectal cancer and non-small cell lung cancer.

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on CTA-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTA-01.

Explore the full profile